Luminex
Luminex Obtains CE Marking for MDx Panel to Detect Flu A/B, RSV, COVID-19
Results are generated in a single workflow from a patient sample, which enables rapid detection for the differential diagnosis of a single pathogen.
DiaSorin Expects 2022 Revenue Growth From Base Business, Luminex as COVID-19 Testing Declines
Premium
DiaSorin CEO Carlo Rosa said that demand for the firm's SARS-CoV-2 tests peaked during the Omicron wave in December and January but declined sharply in recent weeks.
DiaSorin 2021 Revenues Rise 41 Percent on SARS-CoV-2, Luminex Sales Growth
Luminex contributed €195.0 million to DiaSorin's revenues in 2021 and saw strong performance from its Aries and Verigene molecular diagnostic platforms.
Luminex Gets CE Mark for Gastrointestinal Pathogen Panel
The molecular multiplex panel is designed to detect 16 pathogens associated with gastrointestinal infections in stool samples.
Genetic Analysis Receives CE Mark for Microbiome Test on Luminex Magpix Instrument
Receipt of the CE mark will provide the Norwegian firm access to the large number of labs that already have the platform, expanding its addressable market, it said.